Last updated on November 2019

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma


Brief description of study

The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).

Clinical Study Identifier: NCT03568929

Find a site near you

Start Over